![Sample our Engineering & Technology journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5933/TOC-Subject-Sample-2021-Engineering-Tech.jpg"})
Abstract
The time period 6 October 2011 to 5 November 2011 was characterized by a number of major company announcements. Abbott Laboratories, a company that has long prided itself on its diversity, will split into two. The part that will retain the Abbott name will continue this tradition of diversity and the strategy of double-digit growth in earnings per share, albeit, without the pharmaceutical and biopharmaceutical research-based business. This will be spun out as another, yet to be named, publicly traded company. One firm‘s strategic refocusing can, of course, facilitate another‘s strategic development. This is certainly the case in the recent sale by SurModics of its pharmaceutical division to Evonik, where the former‘s decision to concentrate on its device and in vitro diagnostic business opened up an opportunity for the latter to acquire additional formulation, polymer development and manufacturing expertise. Another example of this was Arrowhead‘s purchase of Roche‘s siRNA assets after the Swiss company decided to exit the field. As ever, the article is mainly sourced from company press releases and websites.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.